

Applicants : Michael J. Elliott, et al.
U.S. Serial No: 08/602,272
Filed : February 16, 1996
Page 2

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1-5. (Canceled)

6. (Currently Amended) A method of treating ~~or preventing~~ thrombosis in a subject diagnosed as suffering from thrombosis comprising administering a therapeutically effective amount of an anti-tumor necrosis factor antibody or antigen-binding fragment thereof ~~a tumor necrosis factor antagonist~~ to the subject.

7-8. (Canceled)

9. (Currently Amended) The method of claim 6 ~~8~~, wherein the antibody is selected from the group consisting of a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.

10. (Currently Amended) The method of claim 6 ~~8~~, wherein the antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .

11. (Canceled)

12. (Currently Amended) The method of claim 6 ~~8~~, wherein the

Applicants : Michael J. Elliott, et al.
U.S. Serial No: 08/602,272
Filed : February 16, 1996
Page 3

antibody is a chimeric antibody, said chimeric antibody comprising (a) a non-human variable region specific for TNF or an antigen-binding portion thereof and (b) a human constant region.

13. (Previously Presented) The method of claim 12, wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .
14. (Previously Presented) The method of claim 12, wherein the chimeric antibody is monoclonal antibody cA2.
15. (Previously Presented) The method of claim 12, wherein the chimeric antibody competitively inhibits binding of TNF α to monoclonal antibody cA2.
- 16-28. (Canceled)
29. (Currently Amended) A method of decreasing plasma fibrinogen in a subject diagnosed as suffering from thrombosis comprising administering a therapeutically effective amount of an anti-tumor necrosis factor antibody or antigen-binding fragment thereof ~~a tumor necrosis factor antagonist~~ to the subject.
30. (Canceled)
31. (Currently Amended) The method of claim 29 30, wherein the antibody is selected from the group consisting of a humanized antibody and a resurfaced antibody or antigen-

Applicants : Michael J. Elliott, et al.
U.S. Serial No: 08/602,272
Filed : February 16, 1996
Page 4

binding fragment thereof.

32. (Currently Amended) The method of claim 29 ~~30~~, wherein the antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .
33. (Canceled)
34. (Currently Amended) The method of claim 29 ~~30~~, wherein the antibody is a chimeric antibody, said chimeric antibody comprising (a) a non-human variable region specific for TNF or an antigen-binding portion thereof and (b) a human constant region.
35. (Previously Presented) The method of claim 34, wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNF α .
36. (Previously Presented) The method of claim 34, wherein the chimeric antibody competitively inhibits binding of TNF α to monoclonal antibody cA2.
37. (Previously Presented) The method of claim 34, wherein the chimeric antibody is monoclonal antibody cA2.
- 38-50. (Canceled)